JAGX
Jaguar Health, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
0.93
▲ 0.05 (6.24%)
MARKET · —
Price
Open
0.98
Prev close
0.87
Day high
0.92
Day low
0.82
Volume
74.62K
Market cap
$4.26M
P/E (TTM)
—
52W range
0.73 – 85.40
Trailing performance
Returnvs SPY
1W
-5.24%
-3.9%
1M
-15.73%
-19.5%
3M
-74.99%
-78.1%
6M
-95.93%
-107.0%
YTD
-97.34%
-109.6%
1Y
-98.67%
-118.7%
3Y
-100.00%
-174.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$4.26M
Enterprise value$17.31M
Revenue (TTM)$27.82M
Gross profit$22.89M
EBITDA$-23.19M
Net income$-52.42M
EPS (TTM)$-695.50
Free cash flow$-2.12M
Total cash$3.79M
Total debt$16.65M
Book value / share$-99.20
Shares outstanding4.91M
Float4.64M
Short % of float1.77%
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.15
PEG ratio—
Price / sales—
Price / book—
EV / revenue0.62
EV / EBITDA-0.75
Gross margin82.31%
Operating margin-620.16%
Profit margin-130.85%
Return on equity-548.83%
Return on assets-38.04%
Debt / equity253.29
Current ratio0.74
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $11.51M | $11.69M | $0 | $11.96M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$53.58M | -$38.49M | -$41.30M | -$47.45M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$53.58M | -$38.49M | -$41.30M | -$47.45M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Sep 2025 | -177.80 | -219.80 | -23.6% |
| Jun 2025 | -249.55 | -259.26 | -3.9% |
| Mar 2025 | -378.70 | -584.50 | -54.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders8.16%
Held by institutions0.10%
Institutions holding7
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+1.65M
Net buying
Buy transactions
70
1.97M shares
Sell transactions
2
326.06K shares
Net transactions
+72
Buys less sells
Sell : buy shares
0.2 : 1
Mixed
Insider-held shares
421.53K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Dec 11, 25 | BOCHNOWSKI JAMES J. Director |
— | 6.36K | — | Direct |
| Dec 11, 25 | MICEK JOHN J III Director |
— | 7.38K | — | Direct |
| Dec 11, 25 | KING STEVEN R. PH.D. Officer |
— | 11.74K | — | Direct |
| Dec 11, 25 | CONTE LISA A. Chief Executive Officer |
— | 28.59K | — | Direct |
| Dec 11, 25 | SIEGEL JONATHAN B Director |
— | 7.38K | — | Direct |
| Dec 11, 25 | LIZAK CAROL R. Chief Financial Officer |
— | 11.74K | — | Direct |
| Dec 11, 25 | WOLIN JONATHAN S General Counsel |
— | 11.74K | — | Direct |
| Dec 11, 25 | JAYASURIYA ANULA Director |
— | 5.87K | — | Direct |
| Dec 11, 25 | CHATURVEDI PRAVIN R Officer |
— | 11.74K | — | Direct |
| May 16, 25 | CONTE LISA A. Chief Executive Officer |
— | 2 | — | Direct |
| May 16, 25 | KING STEVEN R. PH.D. Officer |
— | 1 | — | Direct |
| Oct 8, 24 | KING STEVEN R. PH.D. Officer |
— | 4.92K | — | Direct |
| Oct 8, 24 | CONTE LISA A. Chief Executive Officer |
— | 16.50K | — | Direct |
| Oct 8, 24 | LIZAK CAROL R. Chief Financial Officer |
— | 4.28K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOCHNOWSKI JAMES J. |
Director | 6.42K | Stock Award(Grant) |
CHATURVEDI PRAVIN R |
Officer | 11.94K | Stock Award(Grant) |
CONTE LISA A. |
Chief Executive Officer | 29.26K | Stock Award(Grant) |
JAYASURIYA ANULA |
Director | 5.92K | Stock Award(Grant) |
KING STEVEN R. PH.D. |
Officer | 11.88K | Stock Award(Grant) |
LIZAK CAROL R. |
Chief Financial Officer | 11.91K | Stock Award(Grant) |
MICEK JOHN J III |
Director | 7.43K | Stock Award(Grant) |
SIEGEL JONATHAN B |
Director | 7.42K | Stock Award(Grant) |
WOLIN JONATHAN S |
General Counsel | 11.94K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
0.86
+7.93% from price
SMA 20
0.93
-6.22% from price
SMA 50
1.72
-49.68% from price
SMA 100
4.64
-80.01% from price
SMA 200
18.74
-95.37% from price
EMA 12
0.92
+1.16% from price
EMA 26
1.17
-20.80% from price
EMA 50
2.19
-57.62% from price
RSI (14)
32.8
Neutral
MACD (12,26,9)
-0.25
Hist 0.07
ATR (14)
0.11
12.99% of price
Realised vol 30D
156.6%
Annualised
Bollinger upper
1.09
20, 2σ
Bollinger lower
0.76
20, 2σ
50 / 200 cross
Death
1.72 vs 18.74
Trend bias
Below 200
-95.37%
Risk profile
Beta vs SPY
2.70
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
156.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-99.1%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.11
12.99% of price
Beta (reported)
—
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Jaguar Health Inc (JAGX) (Q2 2026) Earnings Call Highlights: Rare Disease Breakthroughs and ...
GuruFocus.com · 2d ago
Jaguar Health Reports Second Quarter 2026 Financials
ACCESS Newswire · 3d ago
Jaguar Health to Hold Investor Webcast August 19 Regarding Q2 2026 Financials & Corporate Updates
ACCESS Newswire · 4d ago
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
ACCESS Newswire · 17d ago
Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog
ACCESS Newswire · 25d ago
Jaguar Health Subsidiary to Provide Crofelemer to Infant in EU for Compassionate Use
MT Newswires · 31d ago
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
ACCESS Newswire · 31d ago
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
ACCESS Newswire · 53d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.